- ABOUTDSR is a leading pharmaceutical company founded in 2008. It aims at developing drugs to protect humans against aging and age-related diseases with initial applications in oncology and metabolic disorders.The long-term goals of DSR is to be a leader in the pharmacological retardation of aging and prevention of age related diseases. The short-term goals are to act on specific growth genes to reduce the side effects of cancer therapy, improve the efficacy of cancer treatment, and treat acromegaly.DSR Pharmaceuticals is developing medicines to:
Prevent age-related diseasesMission: Millenials + Careers + ConscienceSan Francisco, CaliforniaiOnPoverty empowers Millenials with the information and resources they need to pursue careers with purpose. Kip helped drive up iOnPoverty's Twitter engagement by over 300 percent.
Protect from chemotherapyMission: Farmers + Markets + ProsperityLimbe, CameroonAMIS Cameroon bridges the gap between farmers and consumers to reduce hunger and poverty for millions of Cameroonians. Together, Kip and AMIS raised $10,000 for Executive Director, Tambe Harry, to attend the Unreasonable Institute.
Stem cell regenerationMission: Social Change Leaders + Conversations + Beaches
Ixtapa, Mexico
Opportunity Collaboration brings together nonprofit leaders, social entrepreneurs, and social investors to move together towards poverty alleviation. With Kip's help, Opportunity Collaboration's Facebook reach grew by up to 700 percent.Treat acromegalyMission: Social Change Leaders + Conversations + Beaches
Ixtapa, Mexico
Opportunity Collaboration brings together nonprofit leaders, social entrepreneurs, and social investors to move together towards poverty alleviation. With Kip's help, Opportunity Collaboration's Facebook reach grew by up to 700 percent. - WHO WE ARE
Valter LongoFounder & Primary InvestigatorGlobal leader in nutrition, genetics, and pharmacological interventions for longevity and healthspan.Director of the Longevity Institute at University of Southern California.Professor of gerontology and longevity.
John KoptchickChief Scientific AdvisorGlobal leader in research on Growth Hormone Receptor agonists and antagonists.Inventor of Somavert, the first Anti-Growth Hormone Receptor that was then marketed by Pfizer.Published over 300 manuscripts related to molecular aspects of Growth Hormone's structure and action.Distinguished Professor of Molecular Biology, Ohio University.
Brian KennedyShareholder & Scientific AdvisorGlobal leader in aging research.CEO of the Buck Institute for Research on Aging.Editor in Chief, Aging Cell.
Mike AckermannChief Executive OfficerFormer SVP of Commercial at Quintiles.Former VP of Neuroscience and Executive Director of Global Marketing Support at Lilly.PhD in Immunology, University of Penn. MBA, University of North Carolina
Todd MorganChief Scientific OfficerResearch Professor, School of Gerontology, University of Southern California.Ph.D. in Biochemistry, Colorado State University.
Priya BalasubramanianSenior Research ScientistExpert in Transformation of Competent Cells, Gene Expression, Enzyme Assays.Ph.D. in Molecular Biology, University of Southern California.
Sebastian BrandhorstResearch ScientistHeinz Osterburg Prize for Pre-doctoral Research.Ph.D. in Medical Biology, University of Duisburg-Essen.
Richard MarshakSenior Commercial AdvisorFormer head of Global Alliance and Strategic Pricing at Abbott.
VMD University of Pennsylvania, MBA University of Chicago.Joseph AntounChair of the BoardHello 
